Craft
Editas Medicine

Editas Medicine

Patents Pending

500

FY, 2016

Revenue

$25.5 M

FY, 2021

Market Capitalization

$550.6 M

2023-01-20

Editas Medicine Summary

Company summary

Overview
Editas Medicine is a transformative genome editing company that is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. The Company operates through developing and commercializing genome editing technology segment. Editas Medicine is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats technology.
Type
Public
Status
Active
Founded
2013
HQ
Cambridge, MA, US | view all locations
Website
http://www.editasmedicine.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key people

  • James C. Mullen

    James C. Mullen, Chairman, President, and Chief Executive Officer

    • David Litvak

      David Litvak, Associate Director, Technical Operations

    • Harry Gill

      Harry Gill, Senior Vice President, Operations

    • Bruce E. Eaton

      Bruce E. Eaton, Executive Vice President and Chief Business Officer

    Operating MetricsView all

    Patents Pending

    500

    FY, 2016

    Patents Issued

    41

    FY, 2016

    LocationsView all

    3 locations detected

    • Cambridge, MA HQ

      United States

      11 Hurley St

    • Boulder, CO

      United States

      Westview building, 4909 Nautilus Ct N 208 211boulder

    • Cambridge, MA

      United States

      300 Third St

    Editas Medicine Financials

    Summary financials

    Revenue (Q3, 2022)
    $42.0K
    Net income (Q3, 2022)
    ($55.7M)
    Cash (Q3, 2022)
    $210.7M
    EBIT (Q3, 2022)
    ($57.5M)
    Enterprise value
    $361.2M

    Footer menu